share_log
Breakings ·  Aug 9 04:43
Regulus Therapeutics Inc: Ended Q2 2024 With Cash, Cash Equivalents, and Investments of $95.9 Mln; Cash Runway Into H1 2026
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment